<DOC>
	<DOC>NCT01596712</DOC>
	<brief_summary>This study will evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and immunogenicity of QGE031 in Japanese atopic male subjects in order to determine the eligibility of Japanese patients in subsequent clinical studies.</brief_summary>
	<brief_title>Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Immunogenicity of QGE031 in Japanese Atopic Male Subjects</brief_title>
	<detailed_description />
	<criteria>Male Japanese subjects who are atopic as determined by an in vitro test (CAPRAST or MAST test) Serum IgE level must be equal to or greater than 30 IU/mL at screening. Poorly controlled asthma i.e. symptoms of asthma (daytime or nighttime) or use of shortacting beta agonist for relief of asthma (except with exercise) more than once a week Worsening of asthma signs and symptoms prompting a medical intervention within 1 year prior to dosing Severe atopic dermatitis within 1 year prior to dosing, defined by a history of eruption with severe inflammation such as erythema, papule, erosion, infiltration and lichen Severe allergic rhinitis strongly disturbing daily life within 1 year prior to dosing Severe allergic conjunctivitis (e.g., episodes of giant papillary, limbal proliferation, shield ulcer) within 1 year prior to dosing Prior use of XolairÂ® or other antiIgE antibodies Concomitant use of allergy vaccination therapy Other protocoldefined inclusion/exclusion criteria may apply.</criteria>
	<gender>Male</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>November 2012</verification_date>
	<keyword>Allergy,</keyword>
	<keyword>Asthma,</keyword>
	<keyword>Atopic dermatitis,</keyword>
	<keyword>Japanese,</keyword>
	<keyword>QGE031,</keyword>
	<keyword>IgE</keyword>
</DOC>